Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seng Gee Lim

Showing results (11-20 of 241) with videos related to

Pageof 25
Sort By:
Annals of the Academy of Medicine, Singapore|December 23, 2018
Pathway to Hepatitis Elimination and ControlSeng Gee Lim, Guan Huei Lee
Alimentary Pharmacology & Therapeutics|March 4, 2022
Editorial: MAFLD and outcome predictionMark D Muthiah, Seng Gee Lim
Gastroenterology|October 13, 2023
Additional Measures After Stopping Nucleoside Analogues in HbeAg-Negative Chronic Hepatitis B: Better But Not EnoughSeng Gee Lim, Yong Chuan Tan
Liver International : Official Journal of the International Association for the Study of the Liver|February 21, 2020
Hepatitis B: Who to treat? A critical review of international guidelinesDaniel Q Huang, Seng Gee Lim
Clinical Liver Disease|January 25, 2021
Life After s Loss: Impact of Hepatitis B s Antigen Loss on Future Patient OutcomesDaniel Q Huang, Seng Gee Lim
The Korean Journal of Internal Medicine|July 11, 2015
A 2015 roadmap for the management of hepatitis C virus infections in AsiaSeng Gee Lim, Yock Young Dan
Journal of Gastroenterology and Hepatology|August 25, 2007
Applicability of cost-effectiveness analysis to management of chronic hepatitis BYock Young Dan, Seng Gee Lim
Liver International : Official Journal of the International Association for the Study of the Liver|January 5, 2017
When can we stop nucleoside analogues in patients with chronic hepatitis B?Chern Hao Chong, Seng Gee Lim
Current HIV Research|February 4, 2006
Understanding human immunodeficiency virus type 1 and hepatitis C virus coinfectionYee-Joo Tan, Seng Gee Lim, Wanjin Hong
Antiviral Research|July 6, 2006
Understanding the accessory viral proteins unique to the severe acute respiratory syndrome (SARS) coronavirusYee-Joo Tan, Seng Gee Lim, Wanjin Hong
Pageof 25

Showing results (11-20 of 241) with videos related to

Sort By:
Pageof 25
Annals of the Academy of Medicine, Singapore|December 23, 2018
Pathway to Hepatitis Elimination and ControlSeng Gee Lim, Guan Huei Lee
Alimentary Pharmacology & Therapeutics|March 4, 2022
Editorial: MAFLD and outcome predictionMark D Muthiah, Seng Gee Lim
Gastroenterology|October 13, 2023
Additional Measures After Stopping Nucleoside Analogues in HbeAg-Negative Chronic Hepatitis B: Better But Not EnoughSeng Gee Lim, Yong Chuan Tan
Liver International : Official Journal of the International Association for the Study of the Liver|February 21, 2020
Hepatitis B: Who to treat? A critical review of international guidelinesDaniel Q Huang, Seng Gee Lim
Clinical Liver Disease|January 25, 2021
Life After s Loss: Impact of Hepatitis B s Antigen Loss on Future Patient OutcomesDaniel Q Huang, Seng Gee Lim
The Korean Journal of Internal Medicine|July 11, 2015
A 2015 roadmap for the management of hepatitis C virus infections in AsiaSeng Gee Lim, Yock Young Dan
Journal of Gastroenterology and Hepatology|August 25, 2007
Applicability of cost-effectiveness analysis to management of chronic hepatitis BYock Young Dan, Seng Gee Lim
Liver International : Official Journal of the International Association for the Study of the Liver|January 5, 2017
When can we stop nucleoside analogues in patients with chronic hepatitis B?Chern Hao Chong, Seng Gee Lim
Current HIV Research|February 4, 2006
Understanding human immunodeficiency virus type 1 and hepatitis C virus coinfectionYee-Joo Tan, Seng Gee Lim, Wanjin Hong
Antiviral Research|July 6, 2006
Understanding the accessory viral proteins unique to the severe acute respiratory syndrome (SARS) coronavirusYee-Joo Tan, Seng Gee Lim, Wanjin Hong
Pageof 25